

Information about proposed Board of Directors Annual General Meeting 2020

Proposal for re-election of the current members of the Board of Directors:

Håkan Björklund

Chairman

Born 1956. Ph.D. from Karolinska Institutet, Stockholm. Chairman and Board member since 2016.

Other appointments: Industry Executive at Avista Capital Partners.

Previous appointments: CEO of Nycomed. Extensive international background in the life science industry, from both R&D and sales and marketing. Member of the Board of Directors of several international life science companies including Alere, Coloplast, Danisco and Lundbeck. Member of the Board of Directors for Biovitrum 2001–2007.

Shares: 15,800

Independent in relation to the company and its management and in relation to the company's principal shareholders.

Håkan Björklund is proposed for re-election both as member of the Board of Directors and as chairman of the board.

Annette Clancy

Born 1954. BSc Hons Pharmacology from Bath University UK. Board member since 2014.

Other appointments: Non-executive Chair of the Board of Enyo SA. Member of the Board of Directors of Obseva SA. Investor at Jeito Capital, France.

Previous appointments: Senior Advisor, Biopharmaceutical Team of Frazier Healthcare. Chair of the Board of Directors of Genable Therapeutics and Lysogene SA. Non-Executive Board Director of Silence Therapeutics plc. and Clavis Pharma. Head of Transaction and Alliance Management at GlaxoSmithKline.

Shares: 3,414

Independent in relation to the company and its management and in relation to the company's principal shareholders.

Matthew Gantz

Born 1965. BA Princeton University and MBA from Harvard Business School. Board member since 2012.

Other appointments: CEO of OxThera AB. Member of the board of Pennsylvania Life Sciences Association and Marine Corps Scholarship Foundation.

Previous appointments: Executive Vice President of BTG. Founder and CEO of Acureon Pharmaceuticals, President and CEO of Hydrabiosciences Inc., Vice President Europe for Chiron's Biopharmaceutical Division and General Manager for PathoGenesis Europe, as well as a variety of US sales and marketing roles at Abbott Laboratories Diagnostic Division.

Shares: 0

Independent in relation to the company and its management and in relation to the company's principal shareholders.

Lennart Johansson

Born 1955. MBA from Stockholm School of Economics. Board member since 2010.

Other appointments: Member of the management team and Senior Advisor at Patricia Industries (division of Investor AB). Chair of the Board of Bonesupport AB, board member of Vectura Fastigheter AB, Hi3G, Atlas Antibodies AB, Chalmers Ventures and Fastighets AB Tingshuset 13.

Previous appointments: Chairman of the Board of Vectura Fastigheter AB, CEO in b-business partners and Emerging Technologies AB. Board member of SAAB AB, IBX Group AB and Gambro Holding AB.

Shares: 21,200

Independent in relation to the company and its management but dependent in relation to the company's principal shareholders.

Helena Saxon

Born 1970. MSc from Stockholm School of Economics. Board member since 2011.

Other appointments: CFO at Investor AB. Member of the Board of Directors of SEB.

Previous appointments: CFO of Hallvarsson & Halvarsson, Vice President at Investor AB and financial analyst at Goldman Sachs. Board member of Aleris and Mölnlycke Health Care.

Shares: 15,500

Independent in relation to the company and its management but dependent in relation to the company's principal shareholders.

Elisabeth Svanberg

Born 1961. MD and PhD from the University of Gothenburg, Sweden. Associate Professor of surgery. Board member since 2018.

Other appointments: Chief Development Officer at Ixaltis SA in France since 2016. Member of the Board of Directors of PledPharma AB.

Previous appointments: Board member of Follicum AB and of the Swedish American Chamber of Commerce New York. Head of the Established Products Group at Janssen Pharmaceuticals, Development Leader and Head of Medical Affairs (Intercon) at Bristol Myers Squibb. Various senior R&D management roles at Serono International, Switzerland.

Shares: 1,550

Independent in relation to the company and its management and in relation to the company's principal shareholders.

Proposal for election of new member of the Board of Directors:

Staffan Schüberg

Born 1969. BA Hons Business Administration from the London Guildhall University, United Kingdom.

Other appointments: CEO and Member of the Board of Directors of the ESTEVE Group. Member of the Board of Directors of Dizlin Pharmaceuticals AB, The European Federation of Pharmaceutical Industries and Associations (EFPIA) and Corporación Químico Farmacéutico Esteve S.A.

Previous appointments: Mr. Schüberg has extensive experience from the pharmaceutical industry and more than 20 years of experience from Board and executive management roles, including a number of senior positions within Lundbeck A/S, such as Regional Vice President for Southern and Western Europe, President and Chairman of the U.S. operations and Global Chief Commercial Officer on Group level.

Shares: 4,500

Independent in relation to the company and its management and in relation to the company's principal shareholders.